GS71 Stock Overview Engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for GSK Historical stock prices Current Share Price UK£15.97 52 Week High UK£21.57 52 Week Low UK£15.70 Beta 0.33 1 Month Change -1.39% 3 Month Change -12.57% 1 Year Change -3.57% 3 Year Change -33.48% 5 Year Change -39.92% Change since IPO -56.85%
Recent News & Updates
GSK plc Announces First Trial Met Its Primary Endpoint of Progression Free Survival in First Line Advanced Ovarian Cancer Dec 20 GSK plc's Jemperli (dostarlimab) Receives US FDA Breakthrough Therapy Designation for Locally Advanced dMMR/MSI-H Rectal Cancer
GSK plc Announces Results from Planned Interim Analysis of the DREAMM-7 Trial Evaluating Belantamab Mafodotin in Combination with Bortezomib Plus Dexamethasone Dec 10
GSK plc Announces Blenrep Combination China Filing Acceptance Dec 09
Gsk Plc's Fully Liquid Menveo Meningococcal Vaccine Approves by European Commission Nov 27 Linerixibat Shows Positive Phase III Results in Cholestatic Pruritus (Relentless Itch) in Primary Biliary Cholangitis (Pbc) See more updates
GSK plc Announces First Trial Met Its Primary Endpoint of Progression Free Survival in First Line Advanced Ovarian Cancer Dec 20 GSK plc's Jemperli (dostarlimab) Receives US FDA Breakthrough Therapy Designation for Locally Advanced dMMR/MSI-H Rectal Cancer
GSK plc Announces Results from Planned Interim Analysis of the DREAMM-7 Trial Evaluating Belantamab Mafodotin in Combination with Bortezomib Plus Dexamethasone Dec 10
GSK plc Announces Blenrep Combination China Filing Acceptance Dec 09
Gsk Plc's Fully Liquid Menveo Meningococcal Vaccine Approves by European Commission Nov 27 Linerixibat Shows Positive Phase III Results in Cholestatic Pruritus (Relentless Itch) in Primary Biliary Cholangitis (Pbc)
GSK plc Announces Overall Survival Results for Blenrep Nov 15
Third quarter 2024 earnings released: UK£0.014 loss per share (vs UK£0.36 profit in 3Q 2023) Oct 31
GSK plc Announces New Positive Arexvy Data in Younger Adults At Risk Oct 24
GSK plc Announces US Food and Drug Administration Accepts New Drug Application for Treatment of Uncomplicated Urinary Tract Infections in Female Adults and Adolescents Oct 16
GSK plc Announces Positive Headline Results from the Phase III Clinical Trials ANCHOR-1 and ANCHOR-2 Oct 14 Roche/Genentech's Gazyva Poised to Transform Lupus Nephritis Treatment After Positive Phase III Results
GSK plc Presents Positive Data for Arexvy, its Respiratory Syncytial Virus Vaccine Oct 08 Gsk Plc's Menveomeningococcal Vaccine in New Single-Vial, Fully Liquid Presentation Receives Positive European Chmp Opinion Sep 24
GSK plc Reaches Two Confidential Settlements in Cases Filed in California State Court with John Russell Sep 19
GSK plc Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX Sep 18
GSK plc Announces Positive Headline Results of A Phase Ii Trial (Nct06431607) for Its Mrna Seasonal Influenza Vaccine Programme Sep 13
GSK plc Reaches Confidential Settlement in Zantac Litigation with Isaac Dixon Sep 12
GSK plc Provides Update on Phase I/II Therapeutic Herpes Simplex Virus Vaccine Trial Sep 11
GSK plc Announces European Commission Has Authorised Arexvy for Active Immunisation for the Prevention of Lower Respiratory Tract Disease Aug 29 GSK plc Announces Zantac (Ranitidine) Litigation Update GSK plc Receives US Food and Drug Administration Breakthrough Therapy Designation for GSK5764227 Aug 20
Gsk plc Announces Zantac (Ranitidine) Litigation Update Aug 16
GSK plc Announces Zantac (Ranitidine) Litigation Update Aug 06
Second quarter dividend of UK£0.15 announced Aug 02 GSK plc Announces US FDA Expands Jemperli (Dostarlimab-Gxly) Plus Chemotherapy Approval to All Adult Patients with Primary Advanced or Recurrent Endometrial Cancer as the First and Only Immuno-Oncology-Based Treatment to Show an Overall Survival Benefit Aug 02
Second quarter 2024 earnings released: EPS: UK£0.29 (vs UK£0.40 in 2Q 2023) Aug 01 GSK plc Declares Second Interim Dividend for Second Quarter of 2024, Payable on 10 October 2024 Jul 31
GSK plc Announces Blenrep EMA Filing Acceptance Jul 22
GSK plc Begins Shipping Influenza Vaccine Doses for 2024-25 Season Jul 12
GSK's Omjjara (Momelotinib) Receives Approval in Japan for Treatment of Myelofibrosis iTeos Therapeutics, Inc. and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer Jun 18
GSK plc Announces That the US Food and Drug Administration (FDA) Has Approved Arexvy Jun 13
GSK plc (LSE:GSK) acquired Elsie Biotechnologies for $50 million. Jun 08 GSK plc Announces Positive Results from an Interim Analysis of the DREAMM-8 Phase III Head-To-Head Trial Evaluating Belantamab Mafodotin Jun 05
GSK plc Provides Litigation Update May 25
An unknown buyer intended to acquire 4.2% stake in Haleon plc (LSE:HLN) from GSK plc (LSE:GSK) for £1.2 billion. May 18
GSK Announces Intention to Sell Approximately 385 Million Shares in Haleon Gsk plc Announces Board Committee Changes May 09
First quarter dividend of UK£0.15 announced May 03
GSK plc to Report Q2, 2024 Results on Jul 31, 2024 May 03
First quarter 2024 earnings released: EPS: UK£0.26 (vs UK£0.37 in 1Q 2023) May 02 GSK plc Announces the US Food and Drug Administration Accepted the Supplemental Biologics License Application for Jemperli Apr 24
GSK plc Announces Positive Results from the Pivotal Eagle-1 Phase III Trial for Gepotidacin GSK plc Announces US Food and Drug Administration Accepts for Review Biologics License Application for its 5-in-1 Meningococcal ABCWY (MenABCWY) Vaccine Candidate Apr 16
GSK plc, Annual General Meeting, May 08, 2024 Mar 26 GSK plc Appoints Hal Dietz as Member of Nominations & Corporate Governance Committee, Effective 11 March 2024 Mar 09
GSK plc Announces Positive Headline Results from an Interim Analysis of the Dreamm-8 Phase Iii Head-To-Head Trial Evaluating Blenrep (Belantamab Mafodotin) Mar 08
New minor risk - Earnings quality Mar 04 Shareholder Returns GS71 DE Pharmaceuticals DE Market 7D -1.0% -2.5% -2.6% 1Y -3.6% -15.6% 6.9%
See full shareholder returns
Return vs Market: GS71 underperformed the German Market which returned 6.9% over the past year.
Price Volatility Is GS71's price volatile compared to industry and market? GS71 volatility GS71 Average Weekly Movement 3.5% Pharmaceuticals Industry Average Movement 5.4% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.2% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: GS71 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: GS71's weekly volatility (4%) has been stable over the past year.
About the Company Founded Employees CEO Website 1715 70,212 Emma Walmsley www.gsk.com
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines.
Show more GSK plc Fundamentals Summary How do GSK's earnings and revenue compare to its market cap? GS71 fundamental statistics Market cap €64.91b Earnings (TTM ) €3.03b Revenue (TTM ) €37.73b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) GS71 income statement (TTM ) Revenue UK£31.31b Cost of Revenue UK£8.65b Gross Profit UK£22.67b Other Expenses UK£20.15b Earnings UK£2.51b
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) 0.62 Gross Margin 72.39% Net Profit Margin 8.02% Debt/Equity Ratio 119.4%
How did GS71 perform over the long term?
See historical performance and comparison Dividends
4.4% Current Dividend Yield When do you need to buy GS71 by to receive an upcoming dividend? GSK dividend dates Ex Dividend Date Nov 14 2024 Dividend Pay Date Jan 09 2025 Days until Ex dividend 39 days Days until Dividend pay date 17 days
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 12:36 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources GSK plc is covered by 63 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Kamla Singh AlphaValue John Eade Argus Research Company Odile Rundquist Baader Helvea Equity Research
Show 60 more analysts 
